不同剂量雷米普利对早期糖尿病肾病患者血压及肾功能的影响

发布时间：2018-05-18 20:28

本文选题：糖尿病肾病 + 雷米普利　；参考：《中国药房》2017年23期

【摘要】：目的:比较不同剂量雷米普利对早期糖尿病肾病患者血压及肾功能的影响。方法:选取我院2014年5月-2015年12月收治的早期糖尿病肾病患者108例为研究对象,按照随机数字表法分为A、B、C组,各36例。3组患者均口服雷米普利片治疗,A、B、C组剂量分别为5、2.5、1.25 mg,qd,均治疗8周。比较3组患者治疗前后血压(收缩压、舒张压)和肾功能指标[24 h尿蛋白、β2微球蛋白含量和尿白蛋白排泄率(UAE)],并记录不良反应发生情况。结果:治疗前,3组患者血压、肾功能指标比较,差异均无统计学意义(P0.05)。治疗后,3组患者血压、24 h尿蛋白含量、β2微球蛋白含量和UAE均显著降低含量,且A组指标显著低于B、C组,差异均有统计学意义(P0.05);B、C组各项指标比较,差异无统计学意义(P0.05)。3组患者治疗过程中均有低血压、低血糖等不良反应,但停止治疗后均逐渐好转。结论:大剂量雷米普利(5 mg,qd)治疗早期糖尿病肾病效果较好,能明显降低患者血压,减少患者尿蛋白排泄,且并不影响其安全性。
[Abstract]:Objective: to compare the effects of different doses of ramipril on blood pressure and renal function in patients with early diabetic nephropathy. Methods: one hundred and eight patients with early diabetic nephropathy admitted in our hospital from May 2014 to December 2015 were selected as study subjects. 36 patients in each group were treated with Ramipril tablets for 8 weeks. Blood pressure (systolic blood pressure, diastolic blood pressure) and renal function index [24 h urine protein, 尾 2 microglobulin content and urinary albumin excretion rate (UAE)] were compared before and after treatment, and adverse reactions were recorded. Results: there was no significant difference in blood pressure and renal function between the three groups before treatment (P 0.05). After treatment, the urine protein content, 尾 2 microglobulin content and UAE content in blood pressure of the three groups were significantly decreased, and the indexes in group A were significantly lower than those in group C, and the differences were statistically significant. There was no significant difference between the two groups in the course of treatment, such as hypotension, hypoglycemia and other adverse reactions, but gradually improved after stopping treatment. Conclusion: high dose ramipril 5 mg / g QD is effective in the treatment of early diabetic nephropathy. It can significantly reduce the blood pressure and urinary protein excretion of the patients, and does not affect its safety.
【作者单位】：攀钢集团成都医院药剂科;攀钢集团成都医院心血管内科;
【分类号】：R587.2;R692.9

【相似文献】